| Literature DB >> 26064945 |
Wenqing Xia1, Shaohua Wang2, Andrea M Spaeth3, Hengyi Rao4, Pin Wang5, Yue Yang5, Rong Huang5, Rongrong Cai5, Haixia Sun5.
Abstract
We aim to investigate whether decreased interhemispheric functional connectivity exists in patients with type 2 diabetes mellitus (T2DM) by using resting-state functional magnetic resonance imaging (rs-fMRI). In addition, we sought to determine whether interhemispheric functional connectivity deficits associated with cognition and insulin resistance (IR) among T2DM patients. We compared the interhemispheric resting state functional connectivity of 32 T2DM patients and 30 healthy controls using rs-fMRI. Partial correlation coefficients were used to detect the relationship between rs-fMRI information and cognitive or clinical data. Compared with healthy controls, T2DM patients showed bidirectional alteration of functional connectivity in several brain regions. Functional connectivity values in the middle temporal gyrus (MTG) and in the superior frontal gyrus were inversely correlated with Trail Making Test-B score of patients. Notably, insulin resistance (log homeostasis model assessment-IR) negatively correlated with functional connectivity in the MTG of patients. In conclusion, T2DM patients exhibit abnormal interhemispheric functional connectivity in several default mode network regions, particularly in the MTG, and such alteration is associated with IR. Alterations in interhemispheric functional connectivity might contribute to cognitive dysfunction in T2DM patients.Entities:
Mesh:
Year: 2015 PMID: 26064945 PMCID: PMC4430652 DOI: 10.1155/2015/719076
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Demographic and clinical characteristics.
| Items |
T2DM patients |
Healthy controls |
| ||
|---|---|---|---|---|---|
| Mean | SD | Mean | SD | ||
| Age, years | 59.5 | 8.2 | 56.2 | 7.1 | 0.106 |
| Gender, male : female | 16 : 14 | 13 : 15 | 0.599 | ||
| Education levels, years | 9.8 | 3.8 | 10.6 | 3.2 | 0.299 |
| Diabetes duration, years | 10.0 | 5.8 | — | — | — |
| History of smoking, yes : no | 4 : 26 | 6 : 22 | 0.415 | ||
| BMI, kg/m2 | 25.3 | 2.7 | 24.7 | 2.4 | 0.329 |
| Systolic BP, mmHg | 129.0 | 19.7 | 129.5 | 15.0 | 0.895 |
| Diastolic BP, mmHg | 78.4 | 9.4 | 80.5 | 7.4 | 0.342 |
| HbA1c, % (mmol/mol) | 8.0 (64) | 1.6 (17.5) | 5.8 (40) | 0.6 (6.6) | <0.001∗ |
| Fasting glucose, mmol/L | 8.3 | 2.4 | 6.0 | 0.9 | <0.001∗ |
| Fasting serum insulin, | 11.0 | 4.0 | 5.6 | 2.1 | <0.001∗ |
| HOMA-IR | 3.8 | 1.1 | 1.5 | 0.5 | <0.001∗ |
| Triglyceride, mmol/L | 1.5 | 0.7 | 1.4 | 0.7 | 0.814 |
| Total cholesterol, mmol/L | 5.5 | 1.2 | 5.7 | 0.8 | 0.576 |
| LDL-C, mmol/L | 3.4 | 0.8 | 3.4 | 0.5 | 0.996 |
| HDL-C, mmol/L | 1.4 | 0.3 | 1.4 | 0.3 | 0.987 |
| Intima-media thickness, mm | 1.0 | 0.2 | 0.9 | 0.2 | 0.059 |
| Blood pressure lowering medications, yes : no | 10 : 20 | 8 : 20 | 0.695 | ||
| Cholesterol lowering medications, yes : no | 9 : 21 | 3 : 25 | 0.07 | ||
* p < 0.05.
HOMA2-IR, homeostasis model assessment-insulin resistance; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol.
Cognitive scores and depressive symptoms.
| Items |
T2DM patients |
Healthy controls |
| ||
|---|---|---|---|---|---|
| Mean | SD | Mean | SD | ||
| MMSE | 28.7 | 1.1 | 29.1 | 1.3 | 0.196 |
| MoCA | 23.0 | 3.0 | 24.4 | 2.1 | 0.053 |
| AVLT-immediate recall | 18.6 | 4.5 | 20.6 | 2.9 | 0.046∗ |
| AVLT-delayed recall | 6.5 | 2.6 | 6.7 | 1.7 | 0.718 |
| TMT-A | 73.0 | 22.1 | 67.6 | 17.0 | 0.306 |
| TMT-B | 195.2 | 62.3 | 159.1 | 43.4 | 0.014∗ |
| CDT | 3.2 | 0.8 | 3.5 | 0.5 | 0.111 |
| DST | 10.9 | 1.9 | 12.2 | 2.4 | 0.028∗ |
| HAMD | 1.3 | 1.1 | 1.2 | 1.1 | 0.773 |
* p < 0.05.
MMSE, Mini Mental State Exam; MoCA, Montreal Cognitive Assessment; AVLT, Auditory Verbal Learning test; TMT, Trail making test; CDT, Clock drawing test; DST, Digit span test; HAMD, Hamilton Depression Scale.
Comparisons of the brain volumes between groups.
| Brain volume |
T2DM patients |
Healthy controls |
| ||
|---|---|---|---|---|---|
| Mean | SD | Mean | SD | ||
| Gray matter | 578.6 | 21.6 | 585.3 | 29.1 | 0.323 |
| White matter | 529.4 | 23.1 | 531.3 | 25.1 | 0.770 |
| Brain parenchyma | 1108.0 | 36.2 | 1116.6 | 34.8 | 0.363 |
Figure 1The regions which showed significantly decreased VHMC values between groups. Thresholds were set at a corrected p < 0.05, determined by Monte Carlo simulation.
Regions showing significant differences in VMHC between patients and healthy controls.
| Brain regions | MNI coordinates | Peak | Voxels |
|---|---|---|---|
| Decreased in T2DM patients | |||
| Middle temporal gyrus | ±54, −45, 6 | −4.8383 | 289 |
| Middle frontal gyrus | ±45, 45, 24 | −2.0195 | 100 |
| Superior frontal gyrus | ±15, 9, 57 | −5.1613 | 267 |
| Inferior parietal lobule | ±63, −27, 21 | −4.3842 | 97 |
| Anterior cingulate gyrus | ±6, 24, 21 | −3.8309 | 91 |
|
| |||
| Increased in T2DM patients | |||
| Inferior osccipital gyrus | ±36, −72, −9 | 4.7328 | 199 |
| Precentral gyrus | ±36, −27, 63 | 3.2897 | 234 |
A corrected threshold of p < 0.05 determined by Monte Carlo simulation was taken as meaning that there was a significant difference between groups. MNI: Montreal Neurological Institute; cluster size is in mm3.
Figure 2(a) Correlation between TMT-B score and mean VMHC values in middle temporal gyrus (r = −0.404, p = 0.027) in diabetic patients. TMT-B, Trail Making Test-B. (b) Correlation between TMT-B score and mean VMHC values in superior frontal gyrus (r = −0.544, p = 0.002) in diabetic patients. (c) Correlation between HOMA-IR and mean VMHC values in middle temporal gyrus (r = −0.528, p = 0.003, resp.) in diabetic patients. HOMA2-IR, homeostasis model assessment-insulin resistance.